Cvrx Inc (CVRX) Stock Price, Quote & News

Company Profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was...

Industry: Medical Devices

Sector: Healthcare

Phone: 763 416 2840

Fax: 763 416 2841

Website: www.cvrx.com

Address:

9201 West Broadway Avenue, Suite 650, Minneapolis, United States

Twister8 Dec. 11 at 4:15 PM

$CVRX The multi year resident (paid?) pumper has moved on to his next gig: $ABEO

0 · Reply

stocklesnarthefirst Dec. 8 at 6:51 PM

$CVRX lets bounce

0 · Reply

ThickStripe Dec. 5 at 2:27 PM

$CVRX https://clinicaltrials.gov/study/NCT07232030?term=barostim&firstPost=2025-11-01_2025-12-03&rank=1 Trial mentioned on the PS q&a that has been submitted to CMS for Category B approval to cover the cost of the device.

0 · Reply

1111tu Dec. 3 at 8:42 PM

$CVRX sounded like they are confident in meeting or exceeding Q4 guidance.

1 · Reply

MedDevice Dec. 3 at 7:14 PM

$CVRX hallelujah the trial

0 · Reply

MedDevice Dec. 3 at 7:04 PM

$CVRX first question - answer is blame the salesforce transformation but don’t ask for more growth from the new salesforce.

0 · Reply

MedDevice Dec. 3 at 2:52 PM

$CVRX SAME STORE SALES. Anything under 2.1 per quarter / active center is a failure of execution and strategy.

0 · Reply

MedDevice Dec. 2 at 12:15 AM

$CVRX Just noticed the thread on top reps leaving was deleted. Any context as to why?

1 · Reply

1111tu Nov. 24 at 8:32 PM

$CVRX V-Wave going before the FDA for approval of their interatrial shunt.$CVRX https://cardiovascularbusiness.com/topics/clinical/heart-failure/fda-panel-review-first-heart-failure-device-its-kind

2 · Reply

MedDevice Nov. 21 at 1:39 AM

$CVRX What has this person accomplished since 2022 as Chief Strategy Officer at CVRx?

1 · Reply

CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 5, 2025, 10:51 PM EST - 5 weeks ago

CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 4:30 PM EDT - 7 weeks ago

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

Aug 4, 2025, 11:00 PM EDT - 4 months ago

CVRx (CVRX) Q2 Revenue Jumps 15%

Aug 4, 2025, 7:27 PM EDT - 4 months ago

CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:05 PM EDT - 4 months ago

CVRx Reports Second Quarter 2025 Financial and Operating Results

Jul 29, 2025, 8:30 AM EDT - 4 months ago

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 7:30 AM EDT - 5 months ago

CVRx Announces Positive News on Outpatient Payment for Barostim

Jul 2, 2025, 4:02 AM EDT - 5 months ago

CVRx: Sell-Off Ignores Its True Potential

May 28, 2025, 4:30 PM EDT - 7 months ago

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

May 10, 2025, 3:51 PM EDT - 7 months ago

CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript

Apr 24, 2025, 4:30 PM EDT - 8 months ago

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

Apr 9, 2025, 8:45 AM EDT - 8 months ago

CVRx Inc: Overreaction Creates Buying Opportunity

Apr 8, 2025, 8:35 AM EDT - 8 months ago

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

GBX RPM

Apr 7, 2025, 4:05 PM EDT - 8 months ago

CVRx Reports Preliminary First Quarter 2025 Financial Results

Feb 12, 2025, 2:45 PM EST - 10 months ago

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

Feb 4, 2025, 11:00 PM EST - 11 months ago

CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript

Feb 4, 2025, 4:05 PM EST - 11 months ago

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Jan 21, 2025, 4:30 PM EST - 11 months ago

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

Dec 23, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 9:04 PM EST - 1 year ago

CVRx: Impressive Top-Line Growth Seems Priced In

Oct 29, 2024, 10:38 PM EDT - 1 year ago

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript

Oct 18, 2024, 2:08 PM EDT - 1 year ago

CVRx announces new CPT® Category I codes for Barostim

Oct 15, 2024, 4:30 PM EDT - 1 year ago

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

Sep 3, 2024, 8:30 AM EDT - 1 year ago

CVRx Announces Appointment of Two New Board Members

Aug 19, 2024, 4:00 PM EDT - 1 year ago

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 19, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join

Aug 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Seeking CVRx Inc Shareholders To Join Fraud Investigation

Aug 17, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Shareholders Can Join Fraud Investigation With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Investors Encouraged To Participate In Fraud Inquiry With The Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Shareholders Urged To Participate In Fraud Inquiry With The Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 1 year ago

CVRx Inc Shareholders Invited To Join Fraud Inquiry With The Schall Law Firm

Aug 14, 2024, 12:30 AM EDT - 1 year ago

CVRx Inc Investors May Participate In Fraud Investigation With The Schall Law Firm

Aug 13, 2024, 2:00 AM EDT - 1 year ago

CVRx Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 8:30 PM EDT - 1 year ago

CVRx Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:00 PM EDT - 1 year ago

CVRx Inc Investors Can Join Fraud Investigation With The Schall Law Firm

Twister8 Dec. 11 at 4:15 PM

$CVRX The multi year resident (paid?) pumper has moved on to his next gig: $ABEO

0 · Reply

stocklesnarthefirst Dec. 8 at 6:51 PM

$CVRX lets bounce

0 · Reply

ThickStripe Dec. 5 at 2:27 PM

0 · Reply

1111tu Dec. 3 at 8:42 PM

$CVRX sounded like they are confident in meeting or exceeding Q4 guidance.

1 · Reply

MedDevice Dec. 3 at 7:14 PM

$CVRX hallelujah the trial

0 · Reply

MedDevice Dec. 3 at 7:04 PM

$CVRX first question - answer is blame the salesforce transformation but don’t ask for more growth from the new salesforce.

0 · Reply

MedDevice Dec. 3 at 2:52 PM

$CVRX SAME STORE SALES. Anything under 2.1 per quarter / active center is a failure of execution and strategy.

0 · Reply

MedDevice Dec. 2 at 12:15 AM

$CVRX Just noticed the thread on top reps leaving was deleted. Any context as to why?

1 · Reply

1111tu Nov. 24 at 8:32 PM

$CVRX V-Wave going before the FDA for approval of their interatrial shunt.$CVRX https://cardiovascularbusiness.com/topics/clinical/heart-failure/fda-panel-review-first-heart-failure-device-its-kind

2 · Reply

MedDevice Nov. 21 at 1:39 AM

$CVRX What has this person accomplished since 2022 as Chief Strategy Officer at CVRx?

1 · Reply

MedDevice Nov. 18 at 2:08 PM

$CVRX permanent coding doesn’t equal more prior authorization approvals until the clinical data supports the outcomes. 5-7 years from any clinical trial validating evidence to support full coverage.

1 · Reply

JarvisFlow Nov. 17 at 6:23 PM

JP Morgan updates rating for CVRx ( $CVRX ) to Neutral, target set at 13 → 15.

0 · Reply

MedDevice Nov. 14 at 3:59 PM

$CVRX how can this company undertake the largest medical device trial in history? can they actually conduct a 2,000 patient trial in an area that has known to be a dead end for M&M benefit? This will compete with many other trials from more established companies that have made recent investment to these space.

0 · Reply

newfguy Nov. 13 at 5:02 PM

$CVRX this board's biggest cheerleader has gone silent

1 · Reply

MedDevice Nov. 7 at 2:34 PM

$CVRX just to reiterate, using a $28K asp, revenue per center remains flat. Using the recently reported $29K asp, Q3 2025 was again under 2 units per quarter.

0 · Reply

Twister8 Nov. 7 at 5:22 AM

$CVRX dead $$$$

0 · Reply

JarvisFlow Nov. 6 at 7:58 PM

Canaccord Genuity has updated their rating for CVRx ( $CVRX ) to Buy with a price target of 11.

0 · Reply

erevnon Nov. 6 at 3:53 PM

Cantor Fitzgerald maintains CVRx $CVRX at Overweight and raises the price target from $11 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

IN0V8 Nov. 6 at 3:23 PM

$CVRX Buy Canaccord Genuity raises target price to $11 from $9

0 · Reply

Twister8 Nov. 6 at 3:01 PM

$CVRX where is the Donald?

0 · Reply

MedDevice Nov. 6 at 2:48 PM

$CVRX cash position relative to future growth and costs warrant the need for a cash raise.

0 · Reply

Market Cap	221.47M
Revenue (ttm)	51.29M
Net Income (ttm)	-59.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-116.92%
Debt to Equity Ratio	1.03

Volume	154,800
Avg Vol	218,008
Day's Range	N/A - N/A
Shares Out	26.21M
Stochastic %K	18%
Beta	1.29
Analysts	Strong Sell
Price Target	$11.50